Sunshine Biopharma Inc. (SBFM) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Sunshine Biopharma Inc. is a pharmaceutical company operating primarily in Canada through its subsidiary, Nora Pharma Inc., which markets 60 generic prescription drugs. The company also develops proprietary drugs, including K1.1 mRNA for liver cancer and SBFM-PL4 for SARS Coronavirus infections. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | 3 Months Ended June 30, 2026 | 6 Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $9,263,687 | $17,352,452 | - |
| Gross Profit | $2,426,682 (26.2%) | $4,607,672 (26.6%) | - |
| Net Loss | $(1,564,048) | $(2,807,917) | - |
| EPS (Basic) | $(1.15) | $(2.95) | - |
| Cash & Equivalents | - | - | $13,748,301 |
| Total Assets | - | - | $33,632,901 |
| Total Liabilities | - | - | $6,094,899 |
| Shareholders' Equity | - | - | $27,538,002 |
| Operating Cash Flow (6mo) | - | $(2,990,077) | - |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 1.6% quarter-over-quarter and 5.2% year-over-year (6-month) primarily due to the termination of distribution agreements effective December 31, 2025, reducing the product portfolio from 71 to 60 drugs.
- Margin Compression: Gross margin declined from 36.4% to 26.2% (Q2) due to increased costs of finished goods, higher sales rebates, and increased inventory obsolescence.
- Expense Reduction: General & Administrative (G&A) expenses decreased significantly year-over-year. The 6-month decrease was largely driven by the absence of a $1,061,809 intangible asset impairment recorded in the prior year.
- Capital Raising: The company raised approximately $5.1 million in a public offering in May 2026 and received $2.7 million from warrant exercises, significantly boosting cash reserves from $9.1 million to $13.7 million.
Outlook, Risks, and Unusual Items
- Liquidity Outlook: Management estimates existing cash and operating cash flow will fund operations for the next 27 months. However, additional capital will be required for expansion and R&D.
- Legal Settlement: A dispute with former Nora Pharma president Mr. Malek Chamoun was settled on July 8, 2026, for approximately $1.06 million USD. The amount was accrued prior to the period end and paid in August 2026.
- Subsequent Financing: In July 2026, the company entered an At-The-Market (ATM) agreement to sell up to $4 million of stock. Between July and August 2026, it sold 1.43 million shares for $1.72 million in net proceeds.
- R&D Progress: The company received a U.S. patent (No. 12,624,066 B2) for its SBFM-PL4 coronavirus treatment, with an extended expiration date of 2043. Animal testing for K1.1 mRNA liver cancer treatment continues.
- Risks: The company relies heavily on Canadian government drug reimbursement policies. It also faces risks related to the commercialization of its proprietary pipeline and the need for future capital raises.
Investor Verification Checklist
- Verify the impact of the terminated distribution agreements on future revenue stability and the timeline for launching the 22 drugs currently in the pipeline.
- Confirm the burn rate and the sufficiency of the $13.7 million cash balance to sustain operations through the 27-month runway estimate.
- Review the terms of the new ATM offering and the dilution impact of the recent warrant exercises and stock issuances.
- Assess the commercial viability and regulatory timeline for the proprietary K1.1 and SBFM-PL4 drug candidates.
- Monitor the status of the earnout payable and any remaining liabilities related to the Nora Pharma acquisition.